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Abstract 30 
Mitochondrial dysfunction is a pathological feature of Duchenne muscular dystrophy (DMD), 31 
a debilitating and fatal neuromuscular disorder characterised by progressive muscle wasting 32 
and weakness. Mitochondria are a source of cellular ATP, involved in Ca2+ regulation and 33 
apoptotic signalling.  Ameliorating aberrant mitochondrial function has therapeutic 34 
potential for reducing DMD disease severity. The dystrophic mdx mouse exhibits peak 35 
muscle damage at 21-28d which stabilises after 8 weeks. The amino acid taurine is 36 
implicated in mitochondrial health and function, with endogenous concentrations low when 37 
measured during the cycle of peak muscle damage in mdx mice. Using whole soleus and EDL 38 
muscle homogenates from 28- and 70-d mdx mice there was no change in native state 39 
mitochondrial complexes using Blue Native-PAGE. NADH:ubiquinone oxidotreductase 40 
subunit-A9 (NDUFA9) protein abundance was lower in soleus muscle of 28 and 70 d mdx 41 
mice and EDL muscle of 70 d mdx mice compared to same muscles in WT (C57BL10/ScSn) 42 
animals. There were age dependant increases in both NDUFA9 protein abundance and 43 
citrate synthase activity in soleus muscles of mdx and WT mice. There was no change in 44 
abundances of mitochondrial dynamics proteins mitofusin 2 (Mfn2) and mitochondrial 45 
dynamics protein 49 (MiD49).  Taurine administration essentially did not affect any 46 
measurements of mitochondria. Collectively these findings suggest mitochondrial content 47 
and dynamics are not reduced in the mdx mouse regardless of disease severity. We also 48 
elucidate that taurine affords no significant benefit to mitochondrial content or dynamics in 49 
the mdx mouse at either 28 or 70 d. 50 
Abbreviations :Blue native polyacrylamide gel electrophoresis (BN-PAGE); bovine serum 51 
albumin (BSA); citrate synthase (CS); cytochrome C oxidase subunit IV (COX IV); Days (d); 52 
Development Studies Hybridoma Bank (DSHB); Duchenne muscular dystrophy (DMD); 53 
extensor digitorum longus (EDL); mitochondrial ATP production rate (MAPR); mitochondrial 54 
dynamics protein 49 (MiD49); mitofusin 2 (Mfn2); NADH:ubiquinone oxidotreductase 55 
subunit-A9 (NDUFA9); oxidative phosphorylation (OXPHOS); phosphate buffered saline 56 
(PBS); phosphate buffered saline with 0.025% Tween (PBST); reactive oxygen species (ROS); 57 
sarcoplasmic reticulum (SR); SR-calcium ATPase (SERCA); standard deviation (SD); taurine 58 
(tau); Tris-buffered, saline-Tween (TBST); Wild type (WT, C57/BL10ScSn) 59 
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Introduction 60 
Duchenne Muscular Dystrophy (DMD) is a debilitating, progressive and ultimately fatal 61 
neuromuscular disorder affecting approximately 1:3600 live male births (5). Caused by the 62 
absence of the protein dystrophin and the subsequent weakening of the sarcolemma, an 63 
influx of extracellular Ca2+ precedes myofibre necrosis and subsequently progressive muscle 64 
wasting and weakness with age (1). The dystrophin deficient mdx mouse is a well-65 
established animal model of DMD and exhibits many of the pathophysiological symptoms 66 
associated with the disorder (12).  It doesn’t, however, experience progressive muscle 67 
wasting and weakness but rather exhibits an age dependant disease severity, peaking at 21-68 
28 (d)ays at which time it most closely mimics the severity of DMD, before undergoing 69 
successful muscle regeneration and stabilising into adulthood (> 8 weeks)(12).  70 
The structural hypothesis for damage in DMD is centred on this Ca2+ entry and is widely 71 
recognised to precede many of the pathological features seen with DMD (1). Intracellular 72 
Ca2+ is continuously sequestered into the specialised membrane bound store, the 73 
sarcoplasmic reticulum (SR) by the SR-calcium ATPase (SERCA), and hence has a reliance on 74 
ATP supply for continued function.  A further key aspect of dystrophic muscle is the 75 
increased requirement for muscle regeneration as the tissue attempts to repair itself, and 76 
this is another significant ATP consuming pathway in the cell. 77 
Mitochondria are the source of cellular energy, producing ATP through a series of five 78 
multimeric enzyme complexes termed oxidative phosphorylation (OXPHOS) and play an 79 
important role in most cells. The function of each of these complexes is dependent on the 80 
efficient assembly of up to 45 different proteins into a single complex (e.g. complex I, (20)).  81 
The application of blue native polyacrylamide gel electrophoresis (BN-PAGE) allows these 82 
complexes to be visualised. Not only critical to the production of cellular energy via 83 
OXPHOS, mitochondria are also regulators of Ca2+ homeostasis, a source of reactive oxygen 84 
species (ROS) production and act as a regulator of apoptotic signalling (4, 13). Mitochondrial 85 
dysfunction has been suspected to be an important pathogenic feature in Duchenne 86 
muscular dystrophy (18, 23). Potential mechanisms of this contribution could be a result of 87 
the sustained increase in cytosolic Ca2+ in dystrophic muscle exerting a Ca2+ overload on the 88 
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mitochondrial transition pore which eventuates in apoptosis (8) and a consequent 89 
decreased ability to produce ATP.  90 
It has been suggested that mitochondria could be a therapeutic target for reducing the 91 
severity of symptoms in DMD patients (30).  Resting ATP content of dystrophic muscle was 92 
reported to be ~50% of that seen in a healthy cohort (2, 6).  This could be due to a 93 
decreased ability to produce ATP, as analyses of isolated or enriched mitochondrial 94 
preparations demonstrated a reduction in mitochondrial ATP production rate (MAPR) and 95 
OXPHOS capacity in the mdx mouse (18, 30, 32). The decline in ATP could also be due to the 96 
increased rate of ATP consumption, for such processes as driving the increased SERCA 97 
activity necessary to try and maintain Ca2+ homeostasis and/or increased muscle 98 
regeneration.  99 
While not completely understood, it has further been suggested that the reduced 100 
bioenergetic status presented by the reduced ATP in dystrophic muscle may be attributable 101 
to morphologically compromised mitochondria, such as becoming swollen, which alters 102 
mitochondrial function (23).  Necessary for mitochondrial fusion, mitofusin 2 (Mfn2) is 103 
responsible for the maintenance of healthy mitochondrial function, fusing together 104 
damaged mitochondria that would otherwise contribute to excess ROS production and 105 
subsequent muscle damage (33). Mfn2 was increased in the EDL and diaphragm of the 106 
utrophin- dystrophin deficient mouse (29), although it is not known if this is altered in 107 
muscle from the less severely affected mdx mouse. Whilst studies investigating 108 
mitochondrial dynamics previously have examined different proteins involved in 109 
mitochondrial fission, such as Fis1 and Opa1, these proteins are also involved in the fission 110 
of other organelles, such as peroxisomes and so it is not possible to relate findings 111 
specifically to mitochondria (21). Recently, mitochondrial dynamics protein 49 (MiD49) and 112 
MiD51 were identified as mitochondrial specific proteins for fission, involved in recruiting 113 
Drp1 to the outer mitochondrial membrane (31).  MiD49 has only recently been described in 114 
skeletal muscle (39) and whether it is altered in dystrophic muscle is not known.    115 
Taurine is an amino acid found ubiquitously in all mammalian cells, and whilst not classified 116 
as essential has extensively been characterised as vital for healthy muscle function and 117 
development (9, 16). Dystrophin deficiency has been shown to impact taurine metabolism 118 
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(34). In the mdx mouse limb muscle taurine levels have been found to be reduced both 119 
before and during the onset of severe dystropathology (21-28 d), before returning to 120 
endogenous levels as the pathology stabilises into adulthood (70 d) (11, 22). The availability 121 
of sufficient taurine both before and during these critical stages is therefore an area of 122 
interest for the potential attenuation of the dystrophic pathology shown in the mdx mouse. 123 
Taurine deficiency has been studied using a taurine transporter knockout mouse where 124 
intramuscular taurine is almost absent (37). Such studies demonstrate pathological 125 
symptoms indicative of those seen with dystrophin deficiency, indicating that taurine has a 126 
role in mitochondrial function and energy production and may serve as a regulator of 127 
mitochondrial protein synthesis, enhance the activity of the electron transport chain and 128 
protect the mitochondria against excessive ROS generation (14, 15, 17). Of importance to 129 
clinical outcomes, studies administering taurine via whole body supplementation or by 130 
applying directly to muscle preparations have found it effective at improving muscle health 131 
and/or force development (3, 7, 10, 35). Taurine deficiency has also been linked to cell 132 
damage associated with increased oxidative stress (15, 17). One interesting point is that in 133 
cardiomyocytes of rats depleted of taurine by beta-alanine, the activity of mitochondrial 134 
complex I and III, and thus the electron transport chain, was suppressed (17). This was 135 
supported by an apparent decrease in the abundance of complex I subunits ND5 and ND6, 136 
albeit in fractionated samples which presents problems as the total mitochondrial pool was 137 
not assessed (39).  138 
To better understand the impact of disease severity and the potential of taurine as a 139 
substance of  therapeutic benefit to DMD we investigated markers of mitochondrial 140 
content, activity and dynamics in the mdx mouse during both peak (28 d) and stable (70 d) 141 
pathology, using the same mice we described in a recent paper (3). Using whole muscle 142 
homogenates we investigated mitochondrial complexes in their native state by BN-PAGE, 143 
complex sub-units NDUFA9 and COX IV as protein indicators of mitochondrial content, 144 
citrate synthase (CS) as a measure of both mitochondrial content and activity, the 145 
abundance of fusion and fission proteins, Mfn2 and MiD49, respectively, as markers of 146 
mitochondrial dynamics and visualised mitochondrial distribution and abundance through 147 
confocal immunohistochemistry.  148 
 149 
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Materials & Methods 150 
 151 
Animals and supplementation.  152 
All procedures in this study were approved by the La Trobe University Animal Ethics 153 
Committee (approval numbers 12-31, 13-48). Only male mice were used with n=35 mdx and 154 
n=24 wild-type (WT, C57/BL10ScSn) animals in total. Experimental animals were bred at the 155 
La Trobe Animal Research and Teaching Facility using breeding pairs obtained from the 156 
Animal Resource Centre (Western Australia, Australia). The offspring of WT and mdx mice 157 
had access to standard rat chow, water ad libitum and were utilised for experimentation at 158 
either 28 ±1 or 70 ±1 days of age. Maximum litter size grown to maturity was 6 males. There 159 
was no significant difference between body weights of each age group at the age of 160 
experimentation (3). Mdx taurine (tau) breeders and subsequent offspring were 161 
supplemented with continuous access to taurine (2.5% wt/vol) enriched drinking water, 162 
with breeders beginning supplementation at least two weeks prior to mating. This dosage of 163 
supplementation has been demonstrated previously to elevate skeletal muscle taurine 164 
content in mdx mice (3). 165 
Muscle dissection  166 
Mice were anesthetised with an intraperitoneal injection of Nembutal (Sodium 167 
Pentobarbitone) and kept unresponsive to tactile stimuli while the extensor digitorum 168 
longus (EDL) and soleus muscles were excised, blotted clean on filter paper (Whatman No.1) 169 
and weighed, before being snap frozen in liquid nitrogen. All muscles were stored at -80°C 170 
until analysis. Mice were then killed by cardiac excision.  171 
  172 
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Western Blotting 173 
Frozen transverse EDL and soleus cryosections were taken from the midpoint (~30 x 10 µm 174 
28 d animals, ~20 x 10 µm 70 d animals) and immediately placed into a very low [Ca2+] 175 
intracellular relaxing physiological buffer containing (in mM): 129 K+, 36 Na+, 1 free Mg2+ 176 
(10.3 total Mg2+), 90 HEPES, 50 EGTA, 8 ATP, 10 CP, pH 7.10, and an osmolality of 295 ±10 177 
mosmol·kg·H2O
-1). The sections were then diluted 2:1 with 3X SDS solution (0.125 M Tris-178 
HCI, 10% glycerol, 4% SDS, 4 M urea, 10% mercaptoethanol and 0.001% bromophenol blue, 179 
pH 6.8) and kept at room temperature for a further 30 minutes, vortexed at five minute 180 
intervals and stored at -80°C until analysed.  181 
Aliquots of each EDL and soleus sample were pooled together and used to create a 182 
calibration curve for that respective muscle that was run on every gel, allowing comparisons 183 
of whole muscle homogenates across gels (25, 27). Total protein from each sample was 184 
initially separated on 4-15% gradient Criterion TGX Stain Free gels (BioRad, Hercules, CA) 185 
and following UV activation using a Stain Free Imager (BioRad), the densities of the total 186 
lanes were obtained (Image lab software v 5.2, BioRad) and used to ensure equal loading for 187 
subsequent western blotting. 188 
Western blotting was performed to determine the protein abundance of mitochondrial 189 
proteins COX IV, NDUFA9, Mfn2 and MiD49. The western blotting protocol was similar to 190 
that described previously (26). Briefly, a similar amount of protein from skeletal muscle 191 
samples was separated on 4-15% gradient Criterion TGX Stain Free gels (BioRad, Hercules, 192 
CA). Prior to transfer gels were imaged with a Stain Free Imager (BioRad) for total protein 193 
which was quantified for each sample using Image lab software (v 5.2, BioRad). Following 194 
this, using a wet transfer protocol, protein was transferred onto a nitrocellulose membrane 195 
at 100V for 30 min. Following transfer the gel was imaged again and the membrane 196 
incubated in Pierce Miser solution (Pierce, Rockford, IL) for ~10 min and then blocked in 5% 197 
skim milk powder in 1% Tris-buffered, saline-Tween (TBST) for ~2 h at room temperature. 198 
Following blocking, membranes were incubated in primary antibodies overnight at 4°C and 2 199 
h at room temperature. Antibody details and dilutions: cytochrome C oxidase subunit IV 200 
(COX IV, rabbit polyclonal, 1:1000, #4844, Cell Signalling), NADH:ubiquinone 201 
oxidotreductase subunit A9 (NDUFA9, rabbit polyclonal, 1:1000), Mfn2 (rabbit polyclonal, 202 
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1:500 ), MiD49 (rabbit polyclonal, 1:500, see (28, 31). Mdx mice were probed for dystrophin 203 
(mouse monoclonal, 1:500, MANDYS1 clone 3B7, Development Studies Hybridoma Bank 204 
(DSHB), Iowa, OH, USA) to confirm the absence of this protein. All antibodies were all 205 
diluted in 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS) with 0.025% 206 
Tween (PBST).  207 
After washing, membranes were incubated with a secondary antibody (goat anti-mouse IgG 208 
or IgM, goat anti-rabbit IgG, HRP conjugated, 1:60,000) and rinsed in TBST. Bands were 209 
visualized using West Femto chemiluminescent substrate (ThermoScientific, IL, USA) and 210 
images taken and densitometry performed using Image Lab software (BioRad). The positions 211 
of molecular mass markers were captured under white light, and then chemiluminescent 212 
imaging was taken without moving the membrane. Total protein and specific protein 213 
densities were each expressed relative to their respective calibration curves and 214 
subsequently each protein was normalised to the total protein content (27). Data was then 215 
expressed relative to the average of the 28 d WT on a given gel. Representative blots for 216 
figures have been created by superimposing blots on top of the molecular mass marker, 217 
with black lines indicating non congruent images from the same probe. 218 
 219 
Citrate Synthase Activity Assay  220 
For determination of citrate synthase (CS) activity, muscle was accurately weighed (10-21 221 
mg) and homogenised (5 x 5 s, with 5 min on ice between bursts) at 20:1 in buffer 222 
containing 70 mM sucrose, 220 mM D-mannitol, 10 mM HEPES (pH 7.4), 1 mM EGTA. 223 
Measurements were made in whole muscle preparations in duplicate or triplicate. Placed 224 
into a reference cuvette was: 825 µL of 0.1 M Tris buffer, 100 µL of 5’5-dithiobis (2-225 
nitrobenzoic acid) (DNTB, 0.5 mg.mL-1 made in Tris buffer) and 10 µL of acetyl-coA (6 mg.mL-226 
1 made in Tris buffer). The cuvette was placed in a spectrophotometer (LKN Novaspec II, 227 
Pharmacia Biotech, Sweden) and the machine was zeroed at 412 nm. Into individual 228 
cuvettes containing the same components as the reference cuvette, 15 µL of homogenate 229 
was added in addition to 50 µL of oxaloacetate (6.1 mg.mL-1 made in Tris buffer) to initiate 230 
the reaction. Absorbance was recorded at 412nm every 15s for a total of 150 s. The change 231 
in absorbance readings (Δ Abs) were plotted against time integrals (15 s) and linear 232 
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regression used to determine the slope of the response.  The slope between 30 and 90 s 233 
was used to calculate CS activity, which is presented as µmol·min-1·g-1. 234 
 235 
Blue Native PAGE (BN-PAGE) 236 
To assess if mitochondrial complexes were present in their entirety we investigated 237 
mitochondrial complexes utilising BN-PAGE. Samples were cryo-sectioned and placed in Na-238 
EGTA solution (described in whole muscle homogenate section) with 1% Triton-X100 (~30 x 239 
10 µm 28 d animals, ~20 x 10 µm 70 d animals in 100 µL buffer). 10 µL of each sample were 240 
diluted 1:1  in solubilising solution (20 mM Bis-Tris pH 7.0, 50 mM NaCI, 10% glycerol, 0.5% 241 
Coomassie) with 2 µL of loading dye (5% Coomassie blue G, 500 mM ε-amino n-caproic acid, 242 
100 mM Bis-Tris pH 7.0). Samples were loaded onto 4-13% native polyacrylamide gels 243 
(Novex, Invitrogen).  Gels were run for 10 min at 100V, 10 min at 400V and a 45 min at 244 
400V, with a change of buffer between the second and third run. Following separation, 245 
protein was transferred to PVDF membrane for 2 h at 100V. Membranes were stained 246 
(Coomassie blue G, 50% methanol, 10% acetic acid), destained (50% methanol, 10% acetic 247 
acid) and blocked for 2 h using 5% skim milk in TBST. Following blocking, the OXPHOS 248 
antibody cocktail (Mouse, 1:1000, Abcam) was applied and methodology from here to 249 
imaging is as described for Western blotting. Following imaging the remaining portions of 250 
the samples were diluted 1:2 in 3x SDS loading buffer and run on a 4-15% Stain-Free 251 
denaturing gel for the total protein used for quantification of each complex.  252 
 253 
Immunohistochemistry (confocal microscopy)  254 
To visualise COX IV and identify mitochondria in tissue sections, transverse cryosections (8-255 
10 μm) were cut from the midpoint of the EDL and soleus muscles, and mounted on 256 
positively charged microscope slides (Lomb Scientific). Cryosections were left at room 257 
temperature for ~10 min, then the fixative (4% paraformaldehyde in PBS; PFA) added for 30 258 
min. Afterwards, cryosections were washed (3 x 10 min in PBS), followed by immunobuffer 259 
(50 mM glycine, 0.033% saponin, 0.25% BSA, 0.05% sodium azide) and incubation for 2 260 
hours.  COX IV antibody (1:100, same source as western blotting), diluted in immunobuffer 261 
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was added and sections incubated overnight at room temperature in an airtight, saturated 262 
container. Sections were washed with immunobuffer (3 x 10 min), before secondary 263 
antibody (1:2000 in immunobuffer, Donkey anti-rabbit Alexis 488 (Abcam, ab150061)) was 264 
added and sections incubated for 2 hours at room temperature. Sections were then washed 265 
in immunobuffer (10 min) before adding DAPI (1:1000 in immunobuffer, 2 min) for 266 
visualizing nuclei.  A negative control slide was obtained by following the above steps with 267 
the omission of primary antibody, where immunobuffer was used during that incubation 268 
step. Sections were finally washed (2 x 10 min, PBS) before being air-dried, and a coverslip 269 
carefully applied with a drop of ProLong Diamond Antifade Mountant (Thermo Fisher, 270 
P36961), and the coverslip sealed with nail polish. Fluorescently labelled samples were 271 
stored in the dark at -20℃. Images were all taken at the same magnification with a Zeiss 272 
780 confocal laser-scanning microscope (Zeiss AxioObserver Z1, Carl Zeiss Microscopy, 273 
Oberkochen, Germany). 274 
 275 
Statistics 276 
All data are presented as mean ± standard deviation (SD). Comparisons between relevant 277 
groups was performed using a One-way ANOVA of variance, with Holm-Sidak’s post-hoc 278 
analyses. All statistical analysis was performed using GraphPad Prism v 6. Significance was 279 
set at p < 0.05.  280 
  281 
 
11 | P a g e  
 
Results 282 
Mitochondrial complex I, II, IV and V abundances  283 
The abundance of mitochondrial complexes were assessed using BN-PAGE with duplicate 284 
measurements of each sample. No difference in the abundances or the apparent migrations 285 
of complexes I, II, IV or V were found in the soleus muscle of WT, mdx and mdx Tau mice (Fig 286 
1).  287 
NDUFA9 and COX IV protein. 288 
In soleus muscle the mitochondrial marker associated with complex I, NDUFA9, was 289 
decreased by approximately 50% in mdx mice at both 28 and 70 d compared to age 290 
matched WT mice (Fig 1A). 70 d mdx tau mice exhibited an approximate 50% increase in 291 
NDUFA9 protein abundance when compared to the mdx group, this increase was not 292 
observed between 28 d mdx and mdx tau supplemented mice (Fig 2A). NDUFA9 abundance 293 
was elevated significantly with age in both the WT and mdx groups (Fig 2A). EDL NDUFA9 294 
protein abundance was reduced in 28 d mdx mice when compared to the WT, with no 295 
further differences observed with NDUFA9 protein abundance between groups (Fig 2B). 296 
There was no differences in soleus or EDL COX IV protein abundances between any groups 297 
(Fig 2C-D). 298 
Citrate synthase activity. 299 
The enzyme citrate synthase is a validated biomarker for mitochondrial density in skeletal muscle, 300 
and CS activity is widely used as measure of oxidative capacity (19) and thereby was used in the 301 
current study. There was an age specific effect on soleus CS activity, with 70 d old WT, mdx 302 
and mdx tau mice all exhibiting more than two-fold increase relative to the 28 d animals 303 
from the same group (Fig 3A). There were no group specific differences in EDL CS activity at 304 
either 28 or70 d (Fig 3B).  There was approximately 20% less CS activity in 28 d mdx 305 
compared with WT mice, with no further differences observed between groups or ages (Fig 306 
3B). 307 
  308 
  309 
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Mitochondrial dynamics, Mfn2 and MiD49, proteins.  310 
There were no differences observed in the abundance of Mfn2 and MiD49 proteins in either 311 
soleus or EDL muscles in any group (Fig 4). 312 
Immunohistochemistry 313 
Mitochondrial abundance following immunostaining was visualised using confocal 314 
microscopy.  Staining of muscle sections with COX IV antibody revealed a qualitatively 315 
similar abundance of mitochondria across all treatment types (Fig. 5), as observed by 316 
western blot analysis (Fig. 2).  There was no discernible difference in staining intensity 317 
between the EDL and soleus muscles of 28 d mice, but there was heterogeneity of COX IV 318 
staining intensity observed between muscle fibres. Presumably greater COX IV, and 319 
therefore mitochondria, is present in the slow twitch oxidative fibres while a lesser intensity 320 
is presented in the more glycolytic fast twitch fibers.  321 
DAPI stain revealed a higher abundance of centralised myonuclei and infiltration of other 322 
nuclei in both EDL and soleus muscles of 28 d mdx mice, which were present to a lesser 323 
extent in mdx tau treated and WT mice (Fig. 5). This trend was not observed in the soleus 324 
muscle of 70 d mice (Fig. 5).  325 
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Discussion 326 
The current study provides muscle specific insights into the effect of age on mitochondria in 327 
wild-type and the mdx mouse model of DMD. It also addresses whether the benefits of 328 
taurine supplementation on muscle function (3) are due to changes in mitochondrial 329 
content or activity. 330 
We investigated the abundance of whole mitochondrial respiratory complexes I, II, IV and V 331 
in their native state by BN-PAGE and found no differences in the abundances or the relative 332 
migration of these complexes between WT and mdx mice in either 28 d animals, when the 333 
dystrophic phenotype would be active and the most damage occurring, or during stable 334 
stages of muscle damage at 70 d (Fig 1B). The examination of mitochondrial complexes by 335 
BN-PAGE has the advantage of providing information about not only complex abundance 336 
but the formation of individual complexes. Each complex consists of numerous individual 337 
proteins, e.g. complex I has 45 subunits and migrates at ~1,000 kDa when containing its full 338 
complement of protein subunits (38). These data suggest that at least the majority of the 339 
subunits assembled for a given complex, are similar between phenotype and ages.  340 
Given that no differences were seen in mitochondrial complexes, we then went on to 341 
examine two important markers of mitochondrial complex abundance by western blotting 342 
using calibration curves and small sample amounts, which provide the most quantitative 343 
approach (27). The protein NDUFA9 is one of the 45 subunits that comprise mammalian 344 
complex I (24) and has been used previously as a marker of both complex abundance and 345 
total mitochondrial content (39). Interestingly, there was ~two-fold less NDUFA9 protein in 346 
soleus muscle from mdx mice at both 28 and 70 d compared with WT mice (Fig 2A).  In EDL 347 
muscle this was only seen in 70 d animals (Fig 2B). In soleus muscles from both WT and mdx 348 
mice there was ~two-fold increase in NDUFA9 abundances with age (Fig 2A). Given that 349 
NDUFA9 is an ~36 kDa protein, then on its own, it would not be expected to be observed as 350 
a difference in the migration or the abundance of the total Complex I on BN-PAGE. Whilst 351 
NDUFA9 is part of Complex I, it is unclear if a change in its abundance would affect overall 352 
mitochondrial function (24). However the decrease in NDUFA9 protein abundance found 353 
here does coincide with reports of a deficiency in Complex I function that was apparent in 354 
muscle from mdx compared with WT animals (32). It was pleasing that the mitochondrial 355 
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yields were reported in that paper and worth due consideration was the low mitochondrial 356 
yields (10-18%) and a difference in the yields between muscle from mdx and WT mice (32). 357 
Interestingly, in cardiac muscle from mdx mice cardiomyocytes have been shown to exhibit 358 
altered mitochondrial activity that was not evident at the level of isolated mitochondria, 359 
suggesting the problem exists on a cellular as opposed to organelle level (36). Such studies 360 
highlight the importance of investigating mitochondrial function in the context of its role 361 
within the cell as well as in isolation. An important and novel aspect of our study is the use 362 
of whole muscle for all our biochemical analyses including BN-PAGE, western blotting and 363 
CS activity. Studies undertaking mitochondrial research involving centrifugation of tissue 364 
samples may be underestimating mitochondrial content, as recently Wyckelsma et al. (39) 365 
identified approximately 10-40% of mitochondria are discarded and, very importantly, the 366 
yields were different when measuring different mitochondrial proteins and different 367 
samples were used. A further and more detailed description of the issues associated with 368 
quantitative assessment following fractionation of tissue are reported by Murphy and Lamb 369 
(27).   370 
Our second protein marker of mitochondrial abundance was COX IV, has been established 371 
as being essential for complex IV (Cytochrome-c oxidase) function (20). We found no 372 
difference in the protein abundance of COX IV between mdx and WT groups in both soleus 373 
and EDL muscle at both ages (Fig 2D). This, in combination with BN-PAGE data, suggests that 374 
Complex IV is not altered in dystrophic muscle, or as a consequence of age. Qualitative 375 
visualisation of COX IV through confocal microscopy further confirmed these results, 376 
revealing no appreciable difference between muscle types, age and tau treatment (Fig 5). 377 
There was however a fibre specific heterogeneity in the intensity of COX IV, with greater 378 
intensity observed in presumably type I slow twitch oxidative fibres as opposed to glycolytic 379 
type II fibres (Fig 5).  380 
Shown to be strongly associated with mitochondrial content and the ability of the 381 
mitochondria to produce ATP (oxidative capacity) (19), we also investigated CS activity in 382 
muscles from the mdx and WT animals at both ages.  We found no change in CS activity 383 
when comparing soleus muscle from mdx and WT mice, either at 28 or 70 d (Fig 3A). When 384 
the effect of age was examined in soleus muscles, CS activity was increased ~two-fold in 385 
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both mdx and WT mice 70 d mice compared to their respective 28 d mice (Fig 3). 386 
Interestingly this age specific increase was of similar magnitude to that observed in NDUFA9 387 
protein abundance (Fig 2A). Whilst it is tempting to speculate that the NDUFA9 protein 388 
abundance is either responding to or driving the age dependent increase in oxidative 389 
capacity of Complex I in soleus muscle, it cannot explain the decreased NDUFA9 protein 390 
abundance seen in soleus muscle of mdx compared with WT mice. It is clear that further 391 
studies are required to elucidate the reason behind the age related changes in CS activity.  392 
This is the first work to investigate the abundance of the mitochondrial specific dynamics 393 
proteins, Mfn2 and MiD49, in whole skeletal muscle from the mdx mouse. There were no 394 
differences in protein abundances of either Mfn2 or MiD49 across both soleus and EDL 395 
muscles and across groups (Fig 4). Based on the previously published suggestion that total 396 
oxidative capacity (measured as MAPR and OXPHOS) may be reduced in mdx mice, we had 397 
thought mitochondrial dynamics would be increased. It was surprising, therefore, to see 398 
that there was no evidence of altered abundance in Mfn2 or MiD49 in the mdx mouse 399 
during 28 d where the period where peak muscular damage occurs and muscle turnover is 400 
high. Interestingly, a recent study reported a several-fold increase in the abundance of Mfn2 401 
in the EDL muscle of 8 week old utrophin-dystrophin deficient mouse (29). The utrophin-402 
dystrophin deficient mouse model cannot be directly compared with the less severe mdx 403 
mouse model because it experiences a more severe phenotype of muscle damage.  Those 404 
data provide evidence, however, that Mfn2can be upregulated in a compensatory capacity 405 
in response to either increased mitochondrial damage or energy demand that was not seen 406 
in the present study. That study also found an increase in Drp1 (29), although given that 407 
Drp1 is involved with the fission of peroxisomes as well as mitochondria, it limits the 408 
interpretation of that finding in relation specifically to mitochondria. We have recently 409 
reported both Mfn2 and MiD49 to be increased in muscle from aged compared with young 410 
adults, further supporting the dynamic response of these proteins (39). 411 
Previously we identified that taurine supplementation was effective at increasing strength 412 
and improving the histological profile of the tibialis anterior muscle in mdx mice during the 413 
peak damage period of 28 d utilising the same mice and treatment regime as the present 414 
study (3). In the current study we investigated whether the beneficial effects of taurine 415 
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were associated with an increase in markers of oxidative capacity or mitochondrial 416 
abundance. Visualisation of nuclei using fluorescent DAPI staining revealed taurine to have a 417 
seemingly beneficial effect on the visible health of EDL and soleus muscles of 28 d mdx 418 
taurine treated mice, as seen with hematoxylin and eosin staining (3). However, while an 419 
increase in NDUFA9 protein abundance was observed in the 70 d mdx tau mouse when 420 
compared to the non-supplemented mdx mouse there was no effect of taurine on any other 421 
measure of mitochondrial content or activity.  While our current data suggests that taurine 422 
affords no mitochondrial adaptation in the mdx mouse at either 28 or 70 d of age, it remains 423 
that complex I activity can be selectively impaired without detectable changes in complex 424 
content or mitochondrial volume/density. Subsequently a possible mechanism for 425 
functional improvement with taurine supplementation could be a reduction in the 426 
impairment of electron transport secondary to an antioxidant effect at complex I (17). It is 427 
thereby not wholly conclusive in the current study that taurine supplementation did not 428 
elicit some mitochondrial adaptation which requires further investigation.  Future studies 429 
should assess mitochondrial function in situ and include high-resolution respirometry, while 430 
ultrastructural mitochondrial reticular comparison would be of interest to support or refute 431 
the relevance of absolute measures of Mfn2 and MiD49 for mitochondrial dynamics. 432 
Conclusion 433 
Our assessment of mitochondria using an array of approaches (BN-PAGE, western blotting, 434 
confocal microscopy and CS activity) suggest there is no reason to believe that 435 
mitochondrial content is reduced in mdx mouse, at either 28 d when peak damage is 436 
occurring, or at 70 d when the muscle is stabilised. In order to further elucidate this, there is 437 
an absolute need for future functional mitochondria assays to be undertaken in whole 438 
muscle preparations, where the entire mitochondrial pool are represented.  439 
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Figure Legends 445 
Figure 1. Native state complex abundance in soleus muscle of 28 and 70 d WT, mdx and 446 
mdx tau mice. (A) Myosin from the Stain Free gel, indicative of total protein (top), 447 
Representative blot of Blue Native PAGE using OXPHOS cocktail antibody (bottom). (B) 448 
Complex I, II, IV and V abundances normalised to the average of the 28 d WT from 28 d 449 
(solid symbols) and 70 d (open symbols) WT (circles), mdx (triangles) and mdx tau (squares) 450 
mice. One way ANOVA with Holm-Sidak’s post-hoc analyses between relevant groups. Data 451 
presented as data points surrounding means ± SD, n indicated by number of symbols.  452 
Figure 2. Mitochondrial protein abundance in soleus and EDL muscles of 28 and 70 d WT, 453 
mdx and mdx tau mice. Shown for each panel is the myosin from the Stain Free gel, 454 
indicative of total protein (top), the representative Western blot protein (middle), and 455 
quantification of protein abundance (bottom) from 28 d (solid symbols) and 70 d (open 456 
symbols) WT (circles), mdx (triangles) and mdx tau (squares) mice. NDUFA9 in soleus (A) and 457 
EDL (B) and COX IV in soleus (C) and EDL (D), each expressed relative to the 28 d WT.  One 458 
way ANOVA with Holm-Sidak’s post-hoc analyses between relevant groups. Data presented 459 
as data points surrounding means ± SD, n indicated by number of symbols. Lines connecting 460 
different bars indicate significance at p<0.05, *** p<0.001.   461 
Figure 3. Citrate synthase activity in soleus and EDL muscles of 28 d compared 70 d wild-462 
type, mdx and mdx taurine (mdx tau) mice. (A) Soleus citrate synthase activity (B) EDL 463 
citrate synthase activity assay from 28 d (solid symbols) and 70 d (open symbols) WT 464 
(circles), mdx (triangles) and mdx tau (squares) mice. One way ANOVA with Holm-Sidak’s 465 
post-hoc analyses between relevant groups. Data presented as data points surrounding 466 
means ± SD, n indicated by number of symbols. Lines connecting different bars indicate 467 
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 473 
Figure 4. Mitochondrial dynamics protein abundance in soleus and EDL muscles of 28 and 474 
70 d WT, mdx and mdx tau mice. Shown for each panel is the myosin from the Stain Free 475 
gel, indicative of total protein (top), the representative Western blot protein (middle), and 476 
quantification of protein abundance (bottom) from 28 d (solid symbols) and 70 d (open 477 
symbols) WT (circles), mdx (triangles) and mdx tau (squares) mice. (A) Fa9, (B) COX IV, (C) 478 
MfN2 and (D) MiD49 expressed relative to the 28 d WT.  One way ANOVA with Holm-Sidak’s 479 
post-hoc analyses between relevant groups. Data presented as data points surrounding 480 
means ± SD, n indicated by number of symbols. Lines connecting different bars indicate 481 
significance at p<0.05.  482 
 483 
Figure 5. Confocal microscopy imaging of mitochondria and nuclei in 28 d and 70 d wild-484 
type, mdx and mdx taurine mice. Transverse sections of EDL and soleus muscles from 28 485 
and 70 d WT, mdx and mdx tau mice shown at 400 X magnification by confocal laser 486 
scanning microscope. Nuclei are stained blue (DAPI), mitochondria are stained green (COX 487 
IV protein). Greater intensity of color equates to greater abundance of COX IV. Fiber 488 
outlines are evident. Scale bars = 100 µm. Experiments repeated on n = 4 animals for all 489 
groups. 490 
  491 
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